Cellestia Biotech announces that the European Commission has granted CB-103 an orphan designation for the treatment of Acute Lymphoblastic Leukaemia (ALL).

It is an important milestone in the development of CB-103, as it represents an official recognition from EMA that CB-103 looks promising in bringing significant benefit to those affected by ALL.

Read the Press Release